A pharma perspective on the systems medicine and pharmacology of inflammation

Mathematical Biosciences

Volumn 260, Issue , 2015, Pages 2-5

  Lahoz Beneytez, Julio ^a   Schnizler, Katrin ^a   Eissing, Thomas ^a  

^a BAYER AG   (Germany)

Author keywords

Inflammation; Physiologically based models; Systems biology; Systems pharmacology

Indexed keywords

PATHOLOGY; PATIENT TREATMENT; PHYSIOLOGICAL MODELS; PHYSIOLOGY;

BIOLOGICAL PHENOMENA; DISEASE PROGRESSION; INFLAMMATION; INFLAMMATORY DISEASE; MODELLING AND SIMULATIONS; SCIENTIFIC COMMUNITY; SYSTEMS BIOLOGY; TRADITIONAL SYSTEMS;

DISEASES;

CORTICOSTEROID;

ARTICLE; CROHN DISEASE; HUMAN; INFLAMMATION; MEDICAL RESEARCH; MOLECULAR BIOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PHARMACODYNAMICS; PHARMACY; PREDICTION; SIGNAL TRANSDUCTION; SIMULATION; SYSTEMS BIOLOGY; BIOLOGICAL MODEL; DRUG INDUSTRY; PHARMACOLOGY; SYSTEM ANALYSIS;

DRUG INDUSTRY; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; PHARMACOLOGY; SYSTEMS ANALYSIS; SYSTEMS BIOLOGY;

EID: 84921435226     PISSN: 00255564     EISSN: 18793134     Source Type: Journal    
DOI: 10.1016/j.mbs.2014.07.006     Document Type: Article

References (20)

1. Kitano H. Looking beyond the details: a rise in system-oriented approaches in genetics and molecular biology. Curr. Genet. 2002, 41:1-10.
2. FDA, Innovation or stagnation: challenge and opportunity on the critical path to new medical products. Challenges and Opportunities Report - March 2004, 2004.
3. Reis S.E., Berglund L., Bernard G.R., Califf R.M., FitzGerald G.A., Johnson P.C. Reengineering the national clinical and translational research enterprise: the strategic plan of the National Clinical and Translational Science Awards Consortium. Acad. Med.: J. Assoc. Am. Med. Colleges 2010, 85:463.
4. Kuepfer L., Lippert J., Eissing T. Multiscale mechanistic modeling in pharmaceutical research and development, Advances in Systems Biology 2012, Springer, pp. 543-561.
5. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R., Schacht A.L. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 2010, 9:203-214.
6. Hay M., Thomas D.W., Craighead J.L., Economides C., Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 2014, 32:40-51.
7. Mould D., Upton R. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst. Pharmacol. 2012, 1:e6.
8. Mould D., Upton R. Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods. CPT Pharmacometrics Syst. Pharmacol. 2013, 2:e38.
9. Strougo A., Eissing T., Yassen A., Willmann S., Danhof M., Freijer J. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J. Pharmacokinet. Pharmacodyn. 2012, 39:195-203.
10. Krauss M., Burghaus R., Lippert J., Niemi M., Neuvonen P., Schuppert A., Willmann S., Kuepfer L., Görlitz L. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification. Silico Pharmacol. 2013, 1:1-11.
11. Eissing T., Kuepfer L., Becker C., Block M., Coboeken K., Gaub T., Goerlitz L., Jaeger J., Loosen R., Ludewig B., Meyer M., Niederalt C., Sevestre M., Siegmund H.U., Solodenko J., Thelen K., Telle U., Weiss W., Wendl T., Willmann S., Lippert J. A computational systems biology software platform for multiscale modeling and simulation: integrating whole-body physiology, disease biology, and molecular reaction networks. Front. Physiol. 2011, 2:4.
12. Krauss M., Schaller S., Borchers S., Findeisen R., Lippert J., Kuepfer L. Integrating cellular metabolism into a multiscale whole-body model. PLoS Comput. Biol. 2012, 8:e1002750.
13. Schaller S., Willmann S., Lippert J., Schaupp L., Pieber T.R., Schuppert A., Eissing T. A generic integrated physiologically based whole-body model of the glucose-insulin-glucagon regulatory system. CPT Pharmacometrics Syst. Pharmacol. 2013, 2:e65.
14. Huang S.M., Abernethy D.R., Wang Y., Zhao P., Zineh I. The utility of modeling and simulation in drug development and regulatory review. J. Pharm. Sci. 2013, 102:2912-2923.
15. P.K. Sorger, S.R. Allerheiligen, D.R. Abernethy, R.B. Altman, K.L. Brouwer, A. Califano, D.Z. D'Argenio, R. Iyengar, W.J. Jusko, R. Lalonde, Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms, An NIH white paper by the QSP workshop group, NIH Bethesda, 2011, pp. 1-48.
16. Foteinou P.T., Calvano S.E., Lowry S.F., Androulakis I.P. In silico simulation of corticosteroids effect on an NFkB-dependent physicochemical model of systemic inflammation. PLoS One 2009, 4:e4706.
17. Hoffmann A., Levchenko A., Scott M.L., Baltimore D. The IκB-NF-κB signaling module: temporal control and selective gene activation. Science 2002, 298:1241-1245.
18. Dwivedi G., Fitz L., Hegen M., Martin S., Harrold J., Heatherington A., Li C. A multiscale model of interleukin-6-mediated immune regulation in Crohn's disease and its application in drug discovery and development. CPT Pharmacometrics Syst. Pharmacol. 2014, 3:e89.
19. Fang J., Sukumaran S., DuBois D.C., Almon R.R., Jusko W.J. Meta-modeling of methylprednisolone effects on glucose regulation in rats. PLoS One 2013, 8.
20. Lee M.J., Ye A.S., Gardino A.K., Heijink A.M., Sorger P.K., MacBeath G., Yaffe M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149:780-794.